These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 33801192)

  • 21. Real-World Comparative Evaluation of Add-On Glucagon-like Peptide 1 Receptor Agonist in Type 2 Diabetes Treated with or without Insulin.
    Chou HW; Cheng KP; Lin AC; Hung HC; Lin CH; Wang CC; Wu HT; Ou HY
    Pharmaceuticals (Basel); 2022 Dec; 15(12):. PubMed ID: 36559020
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Weight loss in patients with type 2 diabetes receiving once-weekly dulaglutide plus insulin lispro or insulin glargine plus insulin lispro: A post-hoc analysis of the AWARD-4 study across baseline body mass index subgroups.
    Fuechtenbusch M; Aberle J; Heitmann E; Nicolay C; Jung H
    Diabetes Obes Metab; 2019 Jun; 21(6):1340-1348. PubMed ID: 30737891
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study.
    Terauchi Y; Satoi Y; Takeuchi M; Imaoka T
    Endocr J; 2014; 61(10):949-59. PubMed ID: 25029955
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Utilization patterns of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus in Germany: a retrospective cohort study.
    Otto T; Myland M; Jung H; Lebrec J; Richter H; Norrbacka K
    Curr Med Res Opin; 2019 May; 35(5):893-901. PubMed ID: 30328731
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of Switching from Liraglutide or Dulaglutide to Subcutaneous Semaglutide on Glucose Metabolism and Treatment Satisfaction in Patients with Type 2 Diabetes: Protocol for a Multicenter, Prospective, Randomized, Open-Label, Blinded-Endpoint, Parallel-Group Comparison Study (The SWITCH-SEMA 1 Study).
    Nomoto H; Oba-Yamamoto C; Takahashi Y; Takeuchi J; Nagai S; Yokoyama H; Taneda S; Kurihara Y; Aoki S; Kameda H; Cho KY; Nakamura A; Atsumi T; Miyoshi H
    Diabetes Ther; 2021 Mar; 12(3):955-964. PubMed ID: 33491111
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Postpartum treatment with liraglutide in combination with metformin versus metformin monotherapy to improve metabolic status and reduce body weight in overweight/obese women with recent gestational diabetes: A double-blind, randomized, placebo-controlled study.
    Elkind-Hirsch KE; Shaler D; Harris R
    J Diabetes Complications; 2020 Apr; 34(4):107548. PubMed ID: 32046931
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Higher Rates of Persistence and Adherence in Patients with Type 2 Diabetes Initiating Once-Weekly vs Daily Injectable Glucagon-Like Peptide-1 Receptor Agonists in US Clinical Practice (STAY Study).
    Polonsky WH; Arora R; Faurby M; Fernandes J; Liebl A
    Diabetes Ther; 2022 Jan; 13(1):175-187. PubMed ID: 34918213
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program.
    Jendle J; Grunberger G; Blevins T; Giorgino F; Hietpas RT; Botros FT
    Diabetes Metab Res Rev; 2016 Nov; 32(8):776-790. PubMed ID: 27102969
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ANDREW: A Multicenter, Prospective, Observational Study in Patients with Type 2 Diabetes on Persistent Treatment with Dulaglutide.
    Bossi AC; De Mori V; Scaranna C; Veronesi G; Lepore G;
    Diabetes Ther; 2020 Nov; 11(11):2677-2690. PubMed ID: 32974879
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
    Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
    Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-world effectiveness, adherence and persistence among patients with type 2 diabetes mellitus initiating dulaglutide treatment.
    Mody R; Grabner M; Yu M; Turner R; Kwan AYM; York W; Fernández Landó L
    Curr Med Res Opin; 2018 Jun; 34(6):995-1003. PubMed ID: 29271258
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Orally Administered Semaglutide Versus GLP-1 RAs in Patients with Type 2 Diabetes Previously Receiving 1-2 Oral Antidiabetics: Systematic Review and Network Meta-Analysis.
    Nuhoho S; Gupta J; Hansen BB; Fletcher-Louis M; Dang-Tan T; Paine A
    Diabetes Ther; 2019 Dec; 10(6):2183-2199. PubMed ID: 31599391
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5).
    Skrivanek Z; Gaydos BL; Chien JY; Geiger MJ; Heathman MA; Berry S; Anderson JH; Forst T; Milicevic Z; Berry D
    Diabetes Obes Metab; 2014 Aug; 16(8):748-56. PubMed ID: 24762094
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
    Trujillo JM; Nuffer W
    Pharmacotherapy; 2014 Nov; 34(11):1174-86. PubMed ID: 25382096
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
    Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness in Real World of Once Weekly Semaglutide in People with Type 2 Diabetes: Glucagon-Like Peptide Receptor Agonist Naïve or Switchers from Other Glucagon-Like Peptide Receptor Agonists: Results from a Retrospective Observational Study in Umbria.
    Di Loreto C; Minarelli V; Nasini G; Norgiolini R; Del Sindaco P
    Diabetes Ther; 2022 Mar; 13(3):551-567. PubMed ID: 35230650
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advances in the treatment of type 2 diabetes: impact of dulaglutide.
    Thompson AM; Trujillo JM
    Diabetes Metab Syndr Obes; 2016; 9():125-36. PubMed ID: 27217788
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination therapy with once-weekly glucagon like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a case series.
    Lajthia E; Bucheit JD; Nadpara PA; Dixon DL; Caldas LM; Murchie M; Sisson EM
    Pharm Pract (Granada); 2019; 17(4):1588. PubMed ID: 31897252
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Liraglutide Versus Exenatide Once Weekly: Persistence, Adherence, and Early Discontinuation.
    Yu M; Xie J; Fernandez Lando L; Kabul S; Swindle RW
    Clin Ther; 2016 Jan; 38(1):149-60. PubMed ID: 26706658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.